ONVO Profile
Organovo Holdings, Inc. is a biotechnology firm specializing in the development of advanced 3D tissue models that replicate critical aspects of human disease. The company is at the forefront of tissue engineering, utilizing its proprietary NovoGen Bioprinters to create three-dimensional living tissues composed of mammalian cells. These bioprinters are integral to Organovo’s technology platform, which includes sophisticated systems for preparing bio-inks and bioprinting complex multicellular structures.
Organovo’s 3D human tissue platform enables the creation of highly accurate tissue models for preclinical drug testing and research. Key offerings include ExVive human liver and ExVive human kidney tissues, which are used for predictive toxicology and efficacy testing of new pharmaceutical compounds. These tissue models provide researchers and pharmaceutical companies with valuable insights into drug metabolism, toxicity, and efficacy, potentially accelerating the drug development process and improving the success rate of new therapeutics.
The company’s innovative approach extends beyond basic tissue engineering to include applications in personalized medicine and disease modeling. Organovo’s technology aims to bridge gaps in current medical research by providing more relevant and human-representative tissue models. This advancement not only enhances the precision of preclinical testing but also has the potential to contribute to regenerative medicine and tissue replacement therapies.
Founded in 2007 and headquartered in Solana Beach, California, Organovo Holdings, Inc. continues to lead the field of bioprinting and tissue engineering. The company's focus on creating functional, 3D human tissues reflects its commitment to advancing biomedical research and improving the drug development pipeline. Through ongoing innovation and technological development, Organovo strives to make significant contributions to the future of medicine and patient care.
|
